Compare MRK & C Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MRK | C |
|---|---|---|
| Founded | 2000 | 1812 |
| Country | United States | United States |
| Employees | N/A | 226000 |
| Industry | Biotechnology: Pharmaceutical Preparations | Major Banks |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 268.7B | 220.2B |
| IPO Year | 1994 | N/A |
| Metric | MRK | C |
|---|---|---|
| Price | $122.35 | $125.30 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 17 | 16 |
| Target Price | $125.59 | ★ $134.94 |
| AVG Volume (30 Days) | 6.9M | ★ 7.2M |
| Earning Date | 04-30-2026 | 04-14-2026 |
| Dividend Yield | ★ 3.06% | 1.88% |
| EPS Growth | ★ 8.01 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $65,011,000,000.00 | N/A |
| Revenue This Year | $3.61 | $24.26 |
| Revenue Next Year | $5.41 | $3.63 |
| P/E Ratio | ★ N/A | $16.63 |
| Revenue Growth | ★ 1.31 | N/A |
| 52 Week Low | $75.40 | $73.49 |
| 52 Week High | $125.14 | $135.29 |
| Indicator | MRK | C |
|---|---|---|
| Relative Strength Index (RSI) | 67.63 | 51.08 |
| Support Level | $112.49 | $124.60 |
| Resistance Level | $124.57 | $133.62 |
| Average True Range (ATR) | 2.30 | 3.16 |
| MACD | 1.02 | -0.56 |
| Stochastic Oscillator | 97.31 | 43.56 |
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform, led by Keytruda, is a major contributor to overall sales. The company also has a substantial vaccine business aimed at preventing pediatric diseases, as well as Gardasil for human papillomavirus. Additionally, Merck sells animal health-related drugs. From a geographical perspective, 47% of the company's sales are generated from US human health (pharmaceuticals and vaccines).
Citigroup is a global financial powerhouse that orchestrates the movement of $5 trillion in daily transaction volume, serving as the essential connective tissue for the world's most complex multinational corporations. The firm remains a leader on the global stage, servicing 90% of the Fortune 500 through a proprietary network that includes direct membership to over 270 cash-clearing centers and a footprint that spans 94 countries. After a checkered history operating as an overly complex, disjointed firm, steps have been taken to streamline operations, resulting in organization across five segments: services, markets, banking, wealth, and US personal banking.